561
Views
3
CrossRef citations to date
0
Altmetric
Short Report

Characteristics of YouTube videos about the meningococcal B vaccine (4CMenB)

ORCID Icon, &
Pages 2513-2517 | Received 19 Nov 2019, Accepted 01 Feb 2020, Published online: 02 Mar 2020

References

  • Santana S, Lausen B, Bujnowska-Fedak M, Chronaki CE, Prokosch H, Wynn R. Informed citizen and empowered citizen in health: results from an European survey. BMC Fam Pract. 2011;12:20. doi:10.1186/1471-2296-12-20.
  • Covolo L, Ceretti E, Passeri C, Boletti M, Gelatti U. What arguments on vaccinations run through YouTube videos in Italy? A content analysis. Hum Vaccin Immunother. 2017;13(7):1693–99. doi:10.1080/21645515.2017.1306159.
  • Mayer MA, Leis A, Sanz F. Health information on the internet and trust marks as quality indicators: vaccines case study. Aten Primaria. 2009;41(10):534–42. doi:10.1016/j.aprim.2009.02.003.
  • Yiannakoulias N, Slavik C, Chase M. Expressions of pro- and anti-vaccine sentiment on YouTube. Vaccine. 2019;37(15):2057–64. doi:10.1016/j.vaccine.2019.03.001.
  • Briones R, Nan X, Madden K, Waks L. When vaccines go viral: an analysis of HPV vaccine coverage on YouTube. Health Commun. 2012;27(5):478–85. doi:10.1080/10410236.2011.610258.
  • Donzelli G, Palomba G, Federigi I, Aquino F, Cioni L, Verani M, Carducci A, Lopalco P. Misinformation on vaccination: a quantitative analysis of YouTube videos. Hum Vaccin Immunother. 2018;14(7):1654–59. doi:10.1080/21645515.2018.1454572.
  • Basch CH, Zybert P, Reeves R, Basch CE. What do popular YouTubeTM videos say about vaccines? Child Care Health Dev. 2017;43(4):499–503. doi:10.1111/cch.12442.
  • Ekram S, Debiec KE, Pumper MA, Moreno MA. Content and commentary: HPV vaccine and YouTube. J Pediatr Adolesc Gynecol. 2019;32(2):153–57. doi:10.1016/j.jpag.2018.11.001.
  • Hernández-García I, Fernández Porcel C. Characteristics of YouTube™ videos in Spanish about the vaccine against meningococcus B. Vacunas. 2018;19(2):37–43. doi:10.1016/j.vacune.2018.11.002.
  • European Centre for Disease Prevention and Control. Expert opinion on the introduction of the meningococcal B (4CMenB) vaccine in the EU/EEA. Stockholm, Sweden: ECDC; 2017. https://ecdc.europa.eu/sites/portal/files/documents/Introduction-of-4CMenB-vaccine.pdf.
  • Folaranmi T, Rubin L, Martin SW, Patel M, MacNeil JR. Centers for Disease Control (CDC). Use of serogroup B meningococcal vaccines in persons aged ≥10 years at increased risk for serogroup B meningococcal disease: recommendations of the Advisory Committee on Immunization Practices, 2015. MMWR Morb Mortal Wkly Rep. 2015;64(22): 608–12. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4584923/
  • MacNeil JR, Rubin L, Folaranmi T, Ortega-Sanchez IR, Patel M, Martin SW. Use of serogroup B meningococcal vaccines in adolescents and young adults: recommendations of the Advisory Committee on Immunization Practices, 2015. MMWR Morb Mortal Wkly Rep. 2015;64(41):1171–76. https://www.cdc.gov/mmwr/preview/mmwrhtml/mm6441a3.htm
  • Wilkins AL, Snape MD. Emerging clinical experience with vaccines against group B meningococcal disease. Vaccine. 2018;36(36):5470–76. doi:10.1016/j.vaccine.2017.07.056.
  • Witteman HO, Zikmund-Fisher BJ. The defining characteristics of Web 2.0 and their potential influence in the online vaccination debate. Vaccine. 2012;30(25):3734–40. doi:10.1016/j.vaccine.2011.12.039.
  • Betsch C, Brewer NT, Brocard P, Davies P, Gaissmaier W, Haase N, Leask J, Renkewitz F, Renner B, Reyna VF, et al. Opportunities and challenges of Web 2.0 for vaccination decisions. Vaccine. 2012;30(25):3727–33. doi:10.1016/j.vaccine.2012.02.025.
  • Limia Sánchez A, Rivera Ariza S, Sánchez-Cambronero Cejudo L, Andreu Román MM. Utilización de la vacuna Bexsero en España en 2016. Comisión de Salud Pública del Consejo Interterritorial del Sistema Nacional de Salud. Madrid, Spain: Ministerio de Sanidad, Servicios Sociales e Igualdad; 2017. https://www.mscbs.gob.es/profesionales/saludPublica/prevPromocion/vacunaciones/docs/Vacuna_Bexsero.pdf

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.